LYON, France & NEW YORK--(BUSINESS WIRE)--
The MEDICREA group (Paris:ALMED) (Alternext Paris: FR0004178572 - ALMED), PEA-PME eligible, which specializes in the development and manufacturing of innovative implantable solutions for the surgical treatment of spinal pathologies, and world leader in solutions customized for each patient, announces its audited 2015 IFRS annual results, as approved by the Board on April 4, and its sales for the first quarter of 2016.
